DeepMed Research

Cebranopadol

Generic Name: Cebranopadol

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₇FN_₂O

CAS Number: 863513-91-1

Unique Ingredient Identifier: 7GDW9S3GN3

Background: Cebranopadol has been used in trials studying the treatment of Pain, Neoplasms, and Chronic Pain.

Clinical Trials

A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

Phase 3

Active, not recruiting

Conditions: Acute Pain

Interventions: Drug: Placebo
Drug: Cebranopadol

First Posted Date: 2024-08-09

Last Posted Date: 2024-12-13

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 300

Registration Number: NCT06545097

Locations: 🇺🇸
ALLEVIATE 1 Site 001106, Little Rock, Arkansas, United States
🇺🇸
ALLEVIATE 1 Site 001110, Bellaire, Texas, United States
🇺🇸
ALLEVIATE 1 Site 001112, Miami, Florida, United States

and more 1 locations

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Phase 3

Recruiting

Conditions: Acute Pain

Interventions: Drug: Oxycodone IR
Drug: Cebranopadol
Drug: Placebo

First Posted Date: 2024-05-21

Last Posted Date: 2024-12-13

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 240

Registration Number: NCT06423703

Locations: 🇺🇸
Alleviate 2 001113, Houston, Texas, United States
🇺🇸
ALLEVIATE 2 Site 001111, San Antonio, Texas, United States
🇺🇸
ALLEVIATE 2 Site 001108, Sheffield, Alabama, United States

and more 7 locations

Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Cebranopadol 1000 µg
Drug: Oxycodone 30 mg
Drug: Placebo
Drug: Cebranopadol 600 µg
Drug: Oxycodone 60 mg
Drug: Cebranopadol 800 µg

First Posted Date: 2022-08-08

Last Posted Date: 2024-05-09

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 30

Registration Number: NCT05491785

Locations: 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, Netherlands
🇳🇱
Leiden University Medical Centre (LUMC), Leiden, Netherlands

Assessment of Abuse Potential of Cebranopadol in Humans

Phase 1

Completed

Conditions: Human Abuse Potential

Interventions: Drug: Cebranopadol 1000 µg
Drug: Cebranopadol 600 µg
Drug: Placebo
Drug: Oxycodone 40 mg
Drug: Tramadol 600 mg

First Posted Date: 2022-02-25

Last Posted Date: 2022-07-27

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 38

Registration Number: NCT05256108

Locations: 🇺🇸
Ohio Clinical Trials, Columbus, Ohio, United States

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Phase 1

Completed

Conditions: Prolonged QTc Interval
Pharmacokinetic

Interventions: Drug: 100 μg cebranopadol
Drug: Placebo to cebranopadol encapsulated tablets
Drug: 400 mg Moxifloxacin
Drug: 200 μg cebranopadol
Drug: Placebo to moxifloxacin encapsulated tablets
Drug: 400 μg cebranopadol

First Posted Date: 2019-05-21

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 171

Registration Number: NCT03958123

Locations: 🇺🇸
US001 Contract research organization, West Bend, Wisconsin, United States

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Phase 1

Completed

Conditions: Pharmacokinetic

Interventions: Drug: Cebranopadol 200 μg tablet

First Posted Date: 2019-03-20

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 34

Registration Number: NCT03882762

Locations: 🇺🇸
US0002 Contract research organization, Orlando, Florida, United States
🇺🇸
US0001 Contract research organization, Miami, Florida, United States

A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

Phase 1

Completed

Conditions: Abuse, Drug

Interventions: Drug: Cebranopadol 400 micrograms
Drug: Placebo matching hydromorphone
Drug: Cebranopadol 100 micrograms
Drug: Hydromorphone hydrochloride 4 milligrams
Drug: Placebo matching cebranopadol

First Posted Date: 2018-11-29

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 226

Registration Number: NCT03757559

Locations: 🇨🇦
INC Research, Toronto, Ontario, Canada

CORAL XT - Open-label Extension Trial of the CORAL Trial

Phase 3

Completed

Conditions: Pain
Neoplasms
Chronic Pain

Interventions: Drug: Cebranopadol

First Posted Date: 2014-01-09

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 76

Registration Number: NCT02031432

Locations: 🇧🇬
BG008, Sofia, Bulgaria
🇧🇪
BE001, Sint-Niklaas, Belgium
🇧🇬
BG001, Shumen, Bulgaria

and more 19 locations

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

Phase 3

Terminated

Conditions: Pain
Neoplasms
Chronic Pain

Interventions: Drug: Morphine Prolonged Release
Drug: Cebranopadol

First Posted Date: 2013-10-17

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 200

Registration Number: NCT01964378

Locations: 🇭🇺
HU004, Gyula, Hungary
🇧🇬
BG003, Sofia, Bulgaria
🇧🇬
BG004, Varna, Bulgaria

and more 39 locations

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Phase 2

Completed

Conditions: Diabetic Neuropathies
Diabetes Mellitus
Chronic Pain

Interventions: Drug: Cebranopadol 600 µg
Drug: Matching Placebo
Drug: Cebranopadol 300 µg
Drug: Cebranopadol 100 µg
Drug: Pregabalin

First Posted Date: 2013-09-11

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 699

Registration Number: NCT01939366

Locations: 🇦🇹
AT001, Vienna, Austria
🇦🇹
AT004, Senftenberg, Austria
🇦🇹
AT003, Vienna, Austria

and more 79 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy